



Educational Activity Information

Activity Title: Maximizing the Role of GLP-1 Agonists in Our Patients with Type 2 Diabetes

Meeting: 2015 ICHP Annual Meeting

Date: Thursday, September 10, 2015 **Time:** 4:30 p.m.

Location: Drury Lane Theatre and Conference Center
Oakbrook Terrace, IL

ACPE Activity Number: 0204-0000-15-428-L01-P

Activity Type: Application-based

CE Credits: 1 hour (0.1 CEU), no partial credit

Activity Description

This educational activity will provide pharmacists with an overview of new and emerging GLP-1 based therapies. Important differences among the GLP-1 agonists will be reviewed, including preparation and administration technique required for the various agents.

Learning Objectives

After the conclusion of this application-based educational activity, participants should be able to

- Review the effect of GLP-1 on glucose metabolism.
- Compare pathophysiologic mechanisms of GLP-1 agonists to other diabetes medications.
- Discuss the differentiating characteristics of available GLP-1 agonists including long-term safety.
- Explain the importance of proper injection device technique in the preparation and administration of GLP-1 agonists in the management of type 2 diabetes.
- Strategize how to overcome barriers in GLP-1 agonist use.

Target Audience

This continuing pharmacy education activity was planned to meet the needs of pharmacists practicing in hospitals, health systems, and ambulatory clinics, who care for patients with type 2 diabetes mellitus.

Continuing Education Information



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Participants will process CPE credit on the ASHP eLearning portal (<http://elearning.ashp.org>). CPE credit will be reported directly to CPE Monitor.

Faculty

Curtis L. Triplitt, Pharm.D., CDE
Associate Director, Diabetes Research Center, Texas Diabetes Institute
Associate Professor, Department of Medicine, Division of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, Texas

Planned by ASHP Advantage and supported by educational grants from AstraZeneca and Lilly.